Modra

ModraPac005/r

ModraPac005, a tablet formulation of paclitaxel developed by Modra, is currently undergoing Phase I studies. Paclitaxel, a member of the taxane class of chemotherapeutics, is also one of the most frequently applied anti-cancer drugs globally and shares a similar efficacy and toxicity profile with docetaxel. Paclitaxel is generally considered slightly less toxic and also requires IV- administration that is formulated with the toxic excipients chremophor EL and ethanol.
 
With initial focus on taxane-based chemotherapeutics, we will bring our oral formulation technology to other areas of oncology and work together with cancer leaders and innovators to expedite the development of next-generation cancer regimens.
 

 




News

Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
Read more

the IV to Oral switch

improving patient lives
Learn more

Events

No current events
Read more